Precision Biosciences Inc
Precision Biosciences Inc (DTIL) Historical Volatility
DTIL's 30 day historical volatility is 109.76%, in the 100th percentile of readings over the past year. This is a high percentile, meaning Precision Biosciences Inc shares have swung far more than usual. DTIL's 30 day implied volatility sits at 242.43%, with an IV Rank of 65.08%, leaving IV 132.67 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 19, 2026.
Read more
Tracking DTIL historical volatility helps you see how much Precision Biosciences Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, DTIL's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor DTIL 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. DTIL's 30 day historical volatility, or DTIL HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing DTIL's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 19, 2026
As of Nov 19, 2026
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →